Galapagos(GLPG) Newsfilter·2025-04-15 05:30Core Points - Galapagos NV announced the departure of CFO and COO Thad Huston, effective August 1, 2025, for personal and professional reasons [1][2] - Huston joined Galapagos in 2023 to aid in its transformation into a cell therapy company, focusing on a decentralized cell therapy platform [2][3] - CEO Paul Stoffels expressed gratitude for Huston's contributions and emphasized the importance of a smooth transition before his departure [3] Company Overview - Galapagos NV is a global biotechnology company dedicated to transforming patient outcomes through innovative science [1] - The company is currently undergoing a transformation into a focused cell therapy business, leveraging its unique platform to deliver CAR-T therapy with a vein-to-vein time of seven days [3] Future Developments - Galapagos plans to announce Huston's successor in the coming months [2] - The company is also involved in a strategic separation into two public companies, which is expected to bring anticipated benefits and synergies [4]